Previous Next
In patients with chronic rheumatic diseases, misleading symptoms can delay cancer diagnosis. In this study, researchers evaluated whether a metabolic signature could indicate paraneoplasia or reveal concomitant cancer in patients with rheumatic musculoskeletal disease. Metabolic markers were quantified in the sera of 56 patients with rheumatoid arthritis or ankylosing spondylitis and 52 patients without known rheumatic disease. A diagnostic cancer model was developed using levels of acetate, creatine, glycine, formate and the L1/L6 lipid ratio. 

Source(s) :
Karolina Gente et al. Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease. Ann Rheum Dis. 2024 Apr 1:ard-2023-224839 ;

Last press reviews


Gut microbiota is involved in the progression of non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is characterized by an accum...

Elderly women with depression have a higher prevalence of low back pain

Low back pain is a pain in the lumbar vertebrae at the base of the bac...

The renin-angiotensin system in the human brain

The renin-angiotensin system is a hormonal system that regulates blood...